Advertisement
Screener

NEOS Investment Management LLC Historic Quarter Change: Foreign ADRs, Reduced

NEOS Investment Management LLC historic quarter change: Foreign ADRs, Reduced

In depositary receipts for foreign shares (depositary receipts and foreign shares traded over the counter), over 10 quarters from 2023-12-31 to 2026-06-30, NEOS Investment Management LLC opened 0 positions, added to 11, reduced 5 and sold out of 2.

  • Q4 2025: Stock ASCENDIS PHARMA A/S; Country of operation —; Class SPONSORED ADR; Shares before 3,682.
  • Q3 2025: Stock ASCENDIS PHARMA A/S; Country of operation —; Class SPONSORED ADR; Shares before 4,078.
  • Q2 2025: Stock ASCENDIS PHARMA A/S; Country of operation —; Class SPONSORED ADR; Shares before 6,106.
  • Q1 2025: Stock ASCENDIS PHARMA A/S; Country of operation —; Class SPONSORED ADR; Shares before 19,040.

Each consecutive pair of Form 13F-HR filings compared (SEC CIK 2001019), 10 quarters: Q2 2026 (2026-03-31 to 2026-06-30, filed 2026-08-11); Q1 2026 (2025-12-31 to 2026-03-31, filed 2026-05-15); Q4 2025 (2025-09-30 to 2025-12-31, filed 2026-02-17); Q3 2025 (2025-06-30 to 2025-09-30, filed 2025-11-07); Q2 2025 (2025-03-31 to 2025-06-30, filed 2025-08-13); Q1 2025 (2024-12-31 to 2025-03-31, filed 2025-05-15); Q4 2024 (2024-09-30 to 2024-12-31, filed 2025-02-12); Q3 2024 (2024-06-30 to 2024-09-30, filed 2024-11-13); Q2 2024 (2024-03-31 to 2024-06-30, filed 2024-08-14); Q1 2024 (2023-12-31 to 2024-03-31, filed 2024-05-13). Rows for the same security, class and put/call are added together. Value change is the filed value at each quarter end, so it includes the price move. Only the filings held here are compared; the firm's 13F-HR filings go back to the quarter ended 2023-09-30.

QuarterStockCountry of operationClassShares beforeShares afterShare changeValue beforeValue afterValue changeFiled
Q4 2025ASCENDIS PHARMA A/S
CUSIP 04351P101
SPONSORED ADR3,6821,799-1,883$732,018$383,619-$348,3992026-02-17
Q3 2025ASCENDIS PHARMA A/S
CUSIP 04351P101
SPONSORED ADR4,0783,682-396$703,863$732,018+$28,1552025-11-07
Q2 2025ASCENDIS PHARMA A/S
CUSIP 04351P101
SPONSORED ADR6,1064,078-2,028$951,681$703,863-$247,8182025-08-13
Q1 2025ASCENDIS PHARMA A/S
CUSIP 04351P101
SPONSORED ADR19,0406,106-12,934$2,621,237$951,681-$1,669,5562025-05-15
Q2 2024ASCENDIS PHARMA A/S
CUSIP 04351P101
SPONSORED ADR11,16010,837-323$1,687,057$1,477,950-$209,1072024-08-14

Similar Firms

Firm NameCountry13F ValueHoldings
Bahl & Gaynor LLCUnited States$19.830B327
COMMONWEALTH OF PENNSYLVANIA PUBLIC SCHOOL EMPLS RETRMT SYSUnited States$19.628B1,755
Steward Partners Investment Advisory, LLCUnited States$19.609B4,416
MetLife Investment Management, LLCUnited States$19.608B2,765
H&H International Investment, LLCUnited States$20.004B19
Select Equity Group, L.P.United States$19.533B179
Resona Asset Management Co.,Ltd.Japan$20.073B791
Elliott Investment Management L.P.United States$20.115B33
O'SHAUGHNESSY ASSET MANAGEMENT, LLCUnited States$20.123B2,776
M&G PlcUnited Kingdom$19.360B424